These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 34717674

  • 21. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A, Ades L, Baran-Marzack F, Mozziconacci MJ, Penther D, Dobbelstein S, Stamatoullas A, Récher C, Prebet T, Moulessehoul S, Fenaux P, Eclache V.
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [Abstract] [Full Text] [Related]

  • 22. Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype.
    Warnstorf D, Bawadi R, Schienke A, Strasser R, Schmidt G, Illig T, Tauscher M, Thol F, Heuser M, Steinemann D, Davenport C, Schlegelberger B, Behrens YL, Göhring G.
    Genes Chromosomes Cancer; 2021 Jun; 60(6):452-457. PubMed ID: 33486841
    [Abstract] [Full Text] [Related]

  • 23. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C, Burillo-Sanz S, Morales-Camacho RM, Pérez-López O, Suito M, Vargas MT, Caballero-Velázquez T, Carrillo-Cruz E, González J, Bernal R, Pérez-Simón JA.
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji R.
    Haematologica; 2024 Jul 01; 109(7):2157-2164. PubMed ID: 38299605
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
    Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Medeiros LJ, Wang SA.
    Eur J Haematol; 2017 Dec 01; 99(6):536-543. PubMed ID: 28926144
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation].
    Feng D, Wang MY, Liu J, Zhang HX, Chen X, Zhang RL, Zhai WH, Ma QL, Pang AM, Yang DL, Wei JL, He Y, Feng SZ, Han MZ, Jiang EL.
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar 14; 44(3):222-229. PubMed ID: 37356984
    [Abstract] [Full Text] [Related]

  • 33. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Marvin-Peek J, Mason EF, Kishtagari A, Jayani RV, Dholaria B, Kim TK, Engelhardt BG, Chen H, Strickland S, Savani B, Ferrell B, Kassim A, Savona M, Mohan S, Byrne M.
    Transplant Cell Ther; 2023 Jun 14; 29(6):390.e1-390.e10. PubMed ID: 36906277
    [Abstract] [Full Text] [Related]

  • 34. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.
    Cleven AH, Nardi V, Ok CY, Goswami M, Dal Cin P, Zheng Z, Iafrate AJ, Abdul Hamid MA, Wang SA, Hasserjian RP.
    Mod Pathol; 2015 Apr 14; 28(4):552-63. PubMed ID: 25412846
    [Abstract] [Full Text] [Related]

  • 35. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
    Zhang L, McGraw KL, Sallman DA, List AF.
    Leuk Lymphoma; 2017 Aug 14; 58(8):1777-1790. PubMed ID: 27967292
    [Abstract] [Full Text] [Related]

  • 36. Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Sakhdari A, Tang Z, Ok CY, Bueso-Ramos CE, Medeiros LJ, Huh YO.
    Cancer Genet; 2019 Oct 14; 238():18-22. PubMed ID: 31425921
    [Abstract] [Full Text] [Related]

  • 37. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.
    Belickova M, Vesela J, Jonasova A, Pejsova B, Votavova H, Merkerova MD, Zemanova Z, Brezinova J, Mikulenkova D, Lauermannova M, Valka J, Michalova K, Neuwirtova R, Cermak J.
    Oncotarget; 2016 Jun 14; 7(24):36266-36279. PubMed ID: 27167113
    [Abstract] [Full Text] [Related]

  • 38. Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
    Dutta S, Moritz J, Pregartner G, Thallinger GG, Brandstätter I, Lind K, Rezania S, Lyssy F, Reinisch A, Zebisch A, Berghold A, Wölfler A, Sill H.
    Ann Hematol; 2022 Apr 14; 101(4):837-846. PubMed ID: 35083527
    [Abstract] [Full Text] [Related]

  • 39. High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome.
    Gao L, Saeed A, Golem S, Zhang D, Woodroof J, McGuirk J, Ganguly S, Abhyankar S, Lin TL, Cui W.
    Int J Lab Hematol; 2021 Feb 14; 43(1):99-109. PubMed ID: 32812335
    [Abstract] [Full Text] [Related]

  • 40. Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
    Halik A, Tilgner M, Silva P, Estrada N, Altwasser R, Jahn E, Heuser M, Hou HA, Pratcorona M, Hills RK, Metzeler KH, Fenwarth L, Dolnik A, Terre C, Kopp K, Blau O, Szyska M, Christen F, Krönke J, Vasseur L, Löwenberg B, Esteve J, Valk PJM, Duchmann M, Chou WC, Linch DC, Döhner H, Gale RE, Döhner K, Bullinger L, Yoshida K, Damm F.
    J Hematol Oncol; 2024 Aug 19; 17(1):70. PubMed ID: 39160538
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.